The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Central Nervous System Tumors


Central Nervous System Tumors

2008 ASCO Annual Meeting

For a list of disclosures, please use the Disclosure links at the bottom of this page.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


Sort by: title abstract no. first author  |  Search Abstracts

ABSTRACT TITLE FIRST AUTHOR     ABSTRACT NO.
Expression of CD133+ in the brain of a mouse model with a lacZ reporter knock-in at the CD133 locus.

A. Hormigo

2000

Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological properties.

F. F. Lang

2001

Expression of EGFRvIII in brain tumor stem cells.

A. Wong

2002

Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells.

H. Colman

2003

Prognostic value of cancer stem cell expression and growth in glioblastoma.

G. L. Banna

2004

Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study.

H. A. Fine

2005

Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG).

E. G. Shaw

2006

Randomized phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04.

W. Wick Wolfgang

LBA2007

Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen.

E. Quant

2008

Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment.

E. di Tomaso

2009

The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma.

J. R. Perry

2010

Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.

J. H. Sampson

2011

Glioblastoma stem cells mediate immune suppression that can be inhibited with Jak2/Stat3 blockade.

A. B. Heimberger

2012

The effect of hyperglycemia on survival in patients with glioblastoma multiforme.

R. L. Derr

2013

Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM).

S. A. Grossman

2014

Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061.

R. Stupp

2015

A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM).

P. D. Brown

2016

A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma.

B. Neyns

2017

Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase Iib study.

P. Hau

2018

Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: A phase II AINO study.

R. Soffietti

2019

Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601.

J. F. De Groot

2020

Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.

S. A. Wagner

2021

Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.

J. N. Rich

2022

A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma.

P. Nghiemphu

2023

Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials.

K. A. Jaeckle

2024

Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM).

J. L. Clarke

2025

Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients.

A. Desjardins

2026

Recurrence pattern after concomitant radio-chemotherapy in newly diagnosed glioblastoma patients: Correlation with MGMT promoter methylation status.

A. Tosoni

2027

Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM).

A. B. Lassman

2028

Prospective evaluation of meningeal involvement in primary CNS lymphoma (PCNSL).

A. Korfel

2029

Ifosfamide or trofosfamide in patients with intraocular lymphoma: Final report.

K. Jahnke

2030

Vascular endothelial growth factor and matrix metalloprotease in lymphomatous meningitis.

E. T. Wong

2031

Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results.

M. Danova

2032

Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study.

L. E. Abrey

2033

Elevated factor VIII activity is common in patients with newly diagnosed high-grade gliomas.

M. B. Streiff

2035

Plasma IGFBP-2 for prediction of clinical outcomes of patients with gliomas.

Y. Lin

2036

Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT protein expression in a series of glioblastoma (GB) patients.

C. Balañá

2037

A longitudinal prospective study of YKL-40 and matrix metalloproteinase-9 (MMP-9) as serum tumor markers in gliomas.

F. M. Iwamoto

2038

Radiographic and immunologic responses to adjuvant immunotherapy for malignant gliomas.

P. Z. New

2039

Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU).

M. J. van den Bent

2040

The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG.

M. J. Taphoorn

2041

Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM.

D. Mitchell

2042

Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma.

T. T. Batchelor

2043

Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial.

M. Weiler

2044

Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib.

S. R. Plotkin

2045

Impact of preradiation versus postoperative MRI changes in T1w contrast enhanced and FLAIR images on radiation treatment planning.

J. O. Blakeley

2046

Prospective phase II trial for recurrent high-grade gliomas with capacitive coupled low radiofrequency (LRF) hyperthermia.

E. D. Hager

2047

Treatment failure due to intracerebral stem cell-like behavior of glioblastoma (GBM) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea (H)? An analysis of study DE21 and DE40 (Ambrosia).

G. Dresemann

2048

Prospective analysis of endocrine function in children with residual/recurrent low-grade brain tumours treated with high-precision stereotactic conformal radiotherapy.

D. Dutta

2049

A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy.

A. E. Sturdza

2050

Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme.

D. A. Reardon

2051

Patterns of care for 952 patients with newly diagnosed glioblastoma.

L. Bauchet

2052

A phase I trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.

E. J. Wuthrick

2053

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

G. B. Roldán

2054

A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501).

M. R. Rosenfeld

2055

A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide.

U. Lassen

2056

Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).

J. P. Kirkpatrick

2057

Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents.

U. Bode

2058

Spinal reirradiation using the Cyberknife-preliminary efficacy from a single institution.

J. A. Haas

2059

A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas.

R. DeBoer

2060

EGFR/AKT pathways alterations in gliomas.

L. M. Núñez

2061

Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM).

H. S. Friedman

2062

Frequent MGMT gene promoter methylation in brain metastases of melanoma, lung, breast and renal carcinoma.

B. Ingold

2063

Correlation of tumor infiltrating lymphocytes and outcome in primary central nervous system lymphomas.

T. Y. Kang

2064

Sorafenib therapy and CNS hemangioblastomas in individuals with Von Hippel Lindau syndrome.

N. Panakis

2065

Completely endoscopic resection of glioblastomas using a transparent conduit: Proof of concept.

J. Engh

2066

Pre-radiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: A retrospective analysis.

C. Kim

2067

Phase II study of combination BCNU and temozolomide (TMZ) prior to radiotherapy in newly diagnosed anaplastic oligodendroglial tumors.

O. L. Chinot

2068

Feasibility and efficacy of second-line chemotherapy at recurrence for pediatric low-grade gliomas: A comparative population-based study.

K. Scheinemann

2069

Retrospective analysis of patients with leptomeningeal disease (LMD) in the MRI era.

L. M. DeAngelis

2070

Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea.

M. E. Salacz

2071

Open-label, dose confirmation and dosimetry study of Interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM).

S. Shen

2072

The topoisomerase I inhibitor gimatecan exhibits synergistic antitumor activity in combination with imatinib mesylate and everolimus against malignant glioma xenografts.

G. Vassal

2073

Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM).

R. Maron

2074

Phase II trial of recurrent primary CNS lymphoma (PCNSL) treated with pemetrexed.

J. K. Altman

2075

Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma.

U. Bogdahn

2076

Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)--Eudract number 2005-003911-63; NCT00311857.

S. E. Combs

2077

Retreatment with a prolonged temozolomide (TMZ) dosing schedule in patients (pts) with recurrent malignant gliomas (MG).

C. E. Murray

2078

A phase II multicentric trial of fotemustine (FTM) in patients (pts) with recurrent/progressive glioblastoma after radiotherapy plus concomitant and/or adjuvant temozolomide: A GICNO (Gruppo Italiano Cooperativo di Neuro-Oncologia) study.

A. A. Brandes

2079

Pretherapeutic prognostic impact of FDG-PET in high-grade gliomas: A multivariate analysis including all consensual prognostics factors.

C. Colavolpe

2080

α-interferon for recurrent WHO grade 1 meningioma.

M. C. Chamberlain

2081

Association of melanoma with glioblastoma multiforme.

A. S. Desai

2082

A phase II study evaluating systemic sagopilone (ZK-EPO) treatment in patients with recurrent malignant gliomas.

A. Silvani

2083

Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme.

J. A. Quinn

2084

Comparison of dynamic susceptibility contrast MRI with conventional MRI in evaluating tumor response following bevacizumab therapy in recurrent high-grade gliomas.

P. N. Shah

2085

Risk factors and treatment outcomes of spinal recurrence from intracranial germinoma.

K. Ogawa

2086

Maintenance rituximab for CNS lymphoma.

D. E. Ney

2087

A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM).

S. Phuphanich

2088

Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival.

A. Narayana

13000

A phase II trial of sunitinib in patients with recurrent high-grade glioma.

C. Chaskis

13001

MicroRNAs as specific biomarkers for distinguishing between primary and metastatic brain tumors.

D. Nass

13002

Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide.

T. Ryken

13003

The importance of total dose intensity in the treatment of primary central nervous system lymphoma.

D. F. Kraemer

13004

A phase II trial of temolozomide in patients with untreated high grade oligodengroglial brain tumours.

H. K. Gan

13005

Molecular inversion probes (MIPs) identify novel copy number changes in pediatric gliomas.

J. D. Schiffman

13006

Bevacizumab (B) plus irinotecan (I) in progressive multiple pretreated and temozolomide (T) refractory glioblastoma multiforme (GBM): A single center experience using a low dose regimen.

A. Dresemann

13007

Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme.

S. Sathornsumetee

13008

Conditional survival of malignant glioma patients.

J. Hu

13009

A single institution's experience with bevacizumab and cytoxic chemotherapy in progressive malignant glioma.

T. M. Mayer

13010

Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety.

M. J. Gil Gil Sr.

13011

Disease presentation and course in patients with a high number of multiple brain metastases.

C. Nieder

13012

Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.

R. M. Zuniga

13013

Accelerated radiotherapy and temozolomide in adults with newly diagnosed glioblastoma multiforme: A pilot study.

D. N. Korones

13014

The prognostic value of radiological bio-markers for detection of cerebral glioma grades and early evaluation of tumor response to radiation therapy using MRI perfusion and spectroscopy.

M. M. Abdel Wahab

13015

Tegwondo: Development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent brain tumors.

H. M. Strik

13016

Efficacy and safety of long-term administration of temozolomide monotherapy in patients with anaplastic astrocytoma at first relapse.

R. Nishikawa

13017

Nimustine plus teniposide in recurrent glioblastoma.

M. Glas

13018

Severe thrombocytopenia after the first cycle of temozolomide: Who is at risk?

K. Elandt

13019

PPARα agonist fenofibrate inhibits IGF-I - mediated growth and DNA repair responses and sensitizes human glioblastoma cells to cisplatin.

K. Reiss

13020

MGMT promoter methylation status in newly diagnosed glioblastomas: Retrospective analysis from a clinical series of patients.

M. Martinez Garcia

13021




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.